Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Peijia Medical Limited (9996.HK)
Suzhou, CN
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.67% | -11.11% | -23.75% | -21.20% | -11.61% | -21.46% | -15.11% | -33.71% | -83.70% | -81.71% | -81.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+15.8% ★ Q4'25: +66.2% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+8.8% Q4'25: +23.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-14.7% Q4'25: -19.2% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-27.5% Q4'25: -36.2% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-11.7% Q4'25: -31.0% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-0.6% ★ Q4'25: -2.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-3.24× Q4'25: -1.10× (vs Q4'23)
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
38.66M
est: 48.61M (-20.5%)
|
136.53M
est: 167.25M (-18.4%)
|
250.83M
est: 287.67M (-12.8%)
|
441.13M
est: 481.34M (-8.4%)
|
615.48M
est: 623.72M (-1.3%)
|
712.87M
est: 726.66M (-1.9%)
|
931.01M
911.23M – 954.56M
+28.1% YoY
|
1.20B
1.10B – 1.31B
+28.8% YoY
|
1.54B
1.46B – 1.64B
+28.4% YoY
|
2.09B
1.97B – 2.22B
+35.5% YoY
|
2.56B
2.42B – 2.72B
+22.7% YoY
|
| EBITDA |
-190.87M
est: -39.64M (-381.5%)
|
-546.54M
est: -3.05B (+82.1%)
|
-359.91M
est: -8.95B (+96.0%)
|
-348.52M
est: -314.29M (-10.9%)
|
-176.59M
est: -129.40B (+99.9%)
|
-133.85M
est: -474.47M (+71.8%)
|
-607.90M
-623.28M – -594.99M
-28.1% YoY
|
-782.74M
-855.36M – -720.51M
-28.8% YoY
|
-1.01B
-1.07B – -950.38M
-28.4% YoY
|
-1.36B
-1.45B – -1.29B
-35.5% YoY
|
-1.67B
-1.78B – -1.58B
-22.7% YoY
|
| EBIT |
-208.72M
est: -41.42M (-403.9%)
|
-574.03M
est: -840.53M (+31.7%)
|
-395.92M
est: -2.47B (+83.9%)
|
-391.32M
est: -340.40M (-15.0%)
|
-229.70M
est: -35.65B (+99.4%)
|
-196.14M
est: -513.88M (+61.8%)
|
-658.40M
-675.05M – -644.41M
-28.1% YoY
|
-847.75M
-926.41M – -780.36M
-28.8% YoY
|
-1.09B
-1.16B – -1.03B
-28.4% YoY
|
-1.47B
-1.57B – -1.39B
-35.5% YoY
|
-1.81B
-1.92B – -1.71B
-22.7% YoY
|
| Net Income |
-2.07B
est: -220.39M (-838.6%)
|
-574.22M
est: -1.97B (+70.9%)
|
-407.81M
est: -527.88M (+22.7%)
|
-392.53M
est: -234.17M (-67.6%)
|
-226.58M
est: -205.41M (-10.3%)
|
-203.29M
est: -99.75M (-103.8%)
|
5.17M
4.44M – 5.91M
+105.2% YoY
|
95.63M
68.79M – 152.88M
+1,748.1% YoY
|
241.48M
210.87M – 272.09M
+152.5% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
139.10M
est: 81.78M (+70.1%)
|
207.68M
est: 281.37M (-26.2%)
|
365.06M
est: 483.96M (-24.6%)
|
466.62M
est: 523.70M (-10.9%)
|
479.44M
est: 678.61M (-29.3%)
|
446.83M
est: 790.61M (-43.5%)
|
1.01B
991.42M – 1.04B
+28.1% YoY
|
1.30B
1.20B – 1.43B
+28.8% YoY
|
1.67B
1.58B – 1.78B
+28.4% YoY
|
2.27B
2.15B – 2.41B
+35.5% YoY
|
2.78B
2.63B – 2.96B
+22.7% YoY
|
| EPS |
-4.43
est: -0.33 (-1,245.7%)
|
-0.87
est: -0.54 (-61.5%)
|
-0.61
est: -0.54 (-12.3%)
|
-0.58
est: -0.34 (-68.5%)
|
-0.34
est: -0.26 (-30.8%)
|
-0.31
est: -0.15 (-106.7%)
|
0.01
0.01 – 0.01
+105.2% YoY
|
0.17
0.10 – 0.23
+2,066.6% YoY
|
0.36
0.32 – 0.41
+115.4% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 111.5K | 0.65% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 24.0K | 0.44% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 100.9K | 0.29% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 91.6K | 0.39% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 101.1K | 0.28% |
| 6 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 77.3K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yi Zhang | Chairman & Chief Executive Officer | 2M | — |
| Hong Ye | Executive Director & Company Secretary | 1M | female |
| Ping Ye Zhang | Executive Director | 209.2K | female |
| Fong Tan Jian | Chief Technology Officer | — | — |
| Lieh Tsai | Chief Financial Officer | — | male |
| Xiaoxiao Zhuang | Vice President of Sales | — | female |
| Kongrong Pan | Chief Operating Officer | — | male |
| Hing Ling Chau FCIS | Company Secretary | — | female |
| Hongpeng Wang | Vice President of Marketing | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9996.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
